title: Importance of serum SELDI-TOF-MS analysis in the diagnosis of early lung cancer.
abstract: BACKGROUND
  Different methods of diagnosis have been found to be inefficient in terms of screening and early diagnosis of lung cancer. Cancer cells produce proteins whose serum levels may be elevated during the early stages of cancer development. Therefore, those proteins may be recognized as potential cancer markers. The aim of this study was to differentiate healthy individuals and lung cancer cases by analyzing their serum protein profiles and evaluate the efficacy of this method in the early diagnosis of lung cancer.
  
  
  METHODS
  170 patients with lung cancer, 53 under high risk of lung cancer, and 47 healthy people were included in our study. Proteomic analysis of the samples was performed with the SELDI-TOF-MS approach.
  
  
  RESULTS
  The most discriminatory peak of the high risk group was 8141. When tree classification analysis was performed between lung cancer and the healthy control group, 11547 was determined as the most discriminatory peak, with a sensitivity of 85.5%, a specificity of 89.4%, a positive predictive value (PPV) of 96.7% and a negative predictive value (NPV) of 62.7%.
  
  
  CONCLUSIONS
  We determined three different protein peaks 11480, 11547 and 11679 were only present in the lung cancer group. The 8141 peak was found in the high-risk group, but not in the lung cancer and control groups. These peaks may prove to be markers of lung cancer which suggests that they may be used in the early diagnosis of lung cancer.
authors.affiliation: Chest Disease Department, Ataturk Chest Disease and Surgery Research and Education Hospital, Ankara, Turkey.
authors.forename: Cebrail
authors.initials: C
authors.lastname: Simsek
authors.forename: Ozlem
authors.initials: O
authors.lastname: Sonmez
authors.forename: Atilla Ihsan
authors.initials: AI
authors.lastname: Keyf
authors.forename: Ahmet Selim
authors.initials: AS
authors.lastname: Yurdakul
authors.forename: Can
authors.initials: C
authors.lastname: Ozturk
authors.forename: Ozlem
authors.initials: O
authors.lastname: Gulbahar
authors.forename: Fusun
authors.initials: F
authors.lastname: Ozmen
authors.forename: Nurullah
authors.initials: N
authors.lastname: Zengin
authors.forename: Dilek
authors.initials: D
authors.lastname: Kubilay
authors.forename: Senem Ceren
authors.initials: SC
authors.lastname: Karatayli
authors.forename: Mithat
authors.initials: M
authors.lastname: Bozdayi
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D001798:Blood Proteins / Q000032:analysis*; D016022:Case-Control Studies; D042241:Early Diagnosis; D005500:Follow-Up Studies; D006801:Humans; D008168:Lung / Q000378:metabolism*; D008175:Lung Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000209:etiology; D011379:Prognosis; D040901:Proteomics; D012680:Sensitivity and Specificity; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
chemical_list: D014408:Biomarkers, Tumor; D001798:Blood Proteins